Real-Time Quote
 +0.67 / +1.12%
Today’s Change
Today|||52-Week Range
Will AbbVie (ABBV) Disappoint in this Earnings Season? - Analyst Blog
Oct 29 / Zacks.com
Long-term reforms of US tax system required to stop 'deserters'
Oct 19 / FT.com
3 Health Care Picks To Beat Earnings - Earnings ESP
Oct 29 / Zacks.com
M&A deal failure at highest since 2008
Oct 19 / FT.com
Gilead Beats on Q3 Earnings, Sovaldi Sales Fall Sequentially - Analyst Blog
Oct 29 / Zacks.com
Could This Game-Changing Drug Deliver $10 Billion in Sales Within Its First Year?
Oct 18 / MotleyFool.com
Pfizer Q3 Earnings Top Estimates Despite Generic Pressure - Analyst Blog
Oct 28 / Zacks.com
Infinity Pharmaceuticals' Duvelisib Fails in Mid-Stage Study - Analyst Blog
Oct 17 / Zacks.com
Pfizer chief: tax inversions still have "meaningful value"
Oct 28 / FT.com
Pfizer's AstraZeneca pursuit knocked by Shire deal collapse
Oct 17 / FT.com
3 Generics Stocks to Buy Now - Analyst Blog
Oct 28 / Zacks.com
Gilead's Harvoni Receives Notice of Compliance from Canada - Analyst Blog
Oct 17 / Zacks.com
Was AbbVie Inc. Wrong to Abandon Its Deal With Shire plc?
Oct 28 / MotleyFool.com
AbbVie Inc to Shire: It's Not You, It's My Country
Oct 16 / MotleyFool.com
3 Drugs Stocks Driving The Industry Higher
Oct 27 / TheStreet.com
Some inversion deals may survive tax changes
Oct 16 / FT.com
Stock Market News for October 27, 2014 - Market News
Oct 27 / Zacks.com
Shire (SHPG) Shares Crash on Concerns Over AbbVie Buyout - Analyst Blog
Oct 16 / Zacks.com
Shire (SHPG) Gains on Q3 Earnings Beat, Ups Guidance - Analyst Blog
Oct 27 / Zacks.com
Deal doers slam the brakes on
Oct 16 / FT.com
The Silver Economy: Silicon Valley joins quest to 'cure' ageing
Oct 26 / FT.com
3 Reasons AbbVie's Stock Could Rise
Oct 16 / MotleyFool.com
How Gilead Sciences Inc. Isn't Gouging Hepatitis C Patients, in 1 Simple Infographic
Oct 26 / MotleyFool.com
Stocks: 5 things to know before the open
Oct 16 / CNNMoney.com
Shire and AstraZeneca show standalone strength
Oct 24 / FT.com
AbbVie drops proposed $54bn Shire deal
Oct 16 / FT.com
Revlimid: Celgene Corporation's Gift That Keeps on Giving
Oct 23 / MotleyFool.com
 $55 billion deal halted by tax dodge crackdown
Oct 15 / CNNMoney.com
Mylan tweaks $5bn 'inversion' deal
Oct 22 / FT.com
Hedge funds face their worst year since 2011
Oct 15 / FT.com
Biotech Stock Roundup: AbbVie Calls off Shire Acquisition, Will Amgen Consider Breaku...
Oct 22 / Zacks.com
AbbVie drops B#32bn bombshell on Shire
Oct 15 / FT.com
Celgene Corporation's Earnings Preview: Pay Attention to New Kids
Oct 22 / MotleyFool.com
Wednesday Links: The End Of The Relentless Bid
Oct 15 / StockTwits
AbbVie and HP: corporate writing stinks and the CEO is to blame
Oct 22 / FT.com
AbbVie and Shire: the tail of the tax tale
Oct 15 / FT.com
AbbVie Drops Shire Deal, Announces Buyback, Ups Dividend - Analyst Blog
Oct 21 / Zacks.com
Blow to hedge funds as AbbVie reconsiders takeover of Shire
Oct 15 / FT.com
3 Drugs Critical to Johnson & Johnson's Future
Oct 21 / MotleyFool.com
Shire: Inversions row should not (hop)scotch tax competition
Oct 15 / FT.com
AbbVie hits Treasury as Shire deal dies
Oct 20 / FT.com
Stocks: 4 things to know before the open
Oct 15 / CNNMoney.com
Will Abbott Labs (ABT) Miss on Earnings This Quarter? - Analyst Blog
Oct 20 / Zacks.com
CSR agrees to Qualcomm takeover
Oct 15 / FT.com
3 Stocks I'll Buy if the Market Crashes
Oct 20 / MotleyFool.com
AbbVie reconsiders $54bn Shire deal
Oct 14 / FT.com
What Johnson & Johnson Can Tell Us about Gilead Sciences, inc. Stock
Oct 20 / MotleyFool.com
Salix pulls deal amid US tax crackdown
Oct 03 / FT.com

To view my watchlist

Not a member yet?

Sign up now for a free account

Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer.

Morningstar: © 2014 Morningstar, Inc. All Rights Reserved.

Factset: FactSet Research Systems Inc. 2014. All rights reserved.

Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved.

Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor’s Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2014 and/or its affiliates.